A Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kilifi, Kenya.

Ebola Virus Disease Clinical Trial

Official title:

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the BPSC1001 (VSVΔG-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Volunteers in Kilifi, Kenya.

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02296983
• Other study ID #: OXTREC 71-14
• Secondary ID: SSC 2976
• Status: Active, not recruiting
• Phase: Phase 1
• First received: November 11, 2014
• Last updated: April 13, 2016
• Start date: December 2014
• Est. completion date: September 2016

Study information

• Verified date: April 2016
• Source: University of Oxford
• Contact: n/a
• Is FDA regulated: No
• Health authority: Kenya: Pharmacy and Poisons BoardUnited States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Previous Ebola outbreaks have been limited to individual countries and contained by infection control activities. The current outbreak in West Africa is international, and air travel has resulted in a number of infected travellers crossing national borders. There are currently no specific treatments generally available for Ebola and the mortality is high, particularly in countries with limited intensive care facilities. There is currently no vaccine and the personal protection required by healthcare workers treating patients is cumbersome and requires full compliance to be protective.

There is now a consortium (VEBCON collaboration) of four clinical centres (in Kenya, Gabon, Switzerland and Germany), WHO and New Link Genetics (the vaccine manufacturer) under which this study will be conducted. The investigators are conducting this trial, a Phase I, open-label, dose escalation trial, designed to establish safety, tolerability and immunogenicity of two doses of VSVΔG-ZEBOV, an Ebola Virus Vaccine Candidate for the first time in sub-Saharan African populations.

The investigators plan to vaccinate 40 volunteers in Kenya. The trial will be conducted at the KEMRI-CGMR Coast site where healthcare workers (both clinical and laboratory) will be the primary target population as they are likely to be the recipients of a protective vaccine. The investigators will vaccinate a cohort of 20 volunteers at a low dose and then vaccinate a further cohort of 20 volunteers at full dose. Each volunteer will receive one dose of the vaccine. The investigators will follow them up for a period of one year looking to their safety and immunogenicity endpoints.

Description:

This study is being conducted to assess safety and immunogenicity of an experimental ebola vaccine.

An outbreak due to the Ebola Zaire (ZEBOV) strain of unprecedented magnitude and scope and with a high mortality continues to spread across West Africa. No vaccine is currently licensed.

The specific opportunity at hand with rVSVΔG-ZEBOV-GP (BPSC1001) is to achieve long-lasting protective immunity to ZEBOV on a time scale of weeks in humans upon a single-shot vaccination, offering a discrete benefit over prime-boost vaccination protocols. The current outbreak represents a global health emergency and the need for access to therapeutic intervention and vaccines is paramount.

The vaccine investigated in this study might provide a critical tool to suppress future out-breaks of EVD in areas at risk.

This study is 1 of 4 clinical trials currently conducted as part of the WHO-led VEBCON consortium, aiming to generate harmonized data for the rVSVΔG-ZEBOV-GP (BPSC1001) vaccine candidate to allow optimized rapid decisions on dose and safety.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 40
• Est. completion date: September 2016
• Est. primary completion date: February 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• • Have provided written informed consent prior to screening procedures (i.e. participants must be literate).

• Healthy adult male or non-pregnant, non-lactating female, ages 18 to 55 (inclusive) at the time of screening

• Free of clinically significant health problems, as determined by pertinent medical history, clinical examination and blood tests at screening

• Available, able, and willing to participate for all study visits and procedures

• Negative pregnancy-test for female volunteers

• Females, of non-childbearing potential who are post-menopausal (i.e. = one year without menses) or surgically sterilized (tubal ligation, bilateral oophorectomy, or hysterectomy)

• Females, of childbearing potential, who are willing to use effective methods of contraception for 14 days before vaccination and 30 days after vaccination.

• Males who are willing to use effective contraception following vaccination for a period of one week.

• Be willing to minimize blood and body fluid exposure of others for 5 days after vaccination

Exclusion Criteria:

• • History of severe local or systemic reactions to any vaccination or a history of severe allergic reactions.

• Known allergy to the components of the BPSC1001 vaccine product

• Unable or unwilling to stay in the study area for the period of the study and comply with study procedures.

• Ongoing participation in another clinical trial

• Receipt of licensed vaccines within 14 days of planned study immunization (30 days for live vaccines)

• Acute or chronic, clinically significant psychiatric, hematologic, pulmonary, cardiovascular, or hepatic or renal functional abnormality as determined by the investigator based on medical history, physical exam, and/or laboratory screening test

• Any serologic evidence of hepatitis B SAg or HIV infection.

• Any confirmed or suspected immunosuppressive or immunodeficient condition, cytotoxic therapy in the previous 5 years, and/or uncontrolled diabetes

• Have an active malignancy or history of metastatic or hematologic malignancy

• Suspected or known alcohol and/or illicit drug abuse within the past 5 years

• Moderate or severe illness and/or fever >38°C within 2 weeks prior to vaccination

• Pregnant or lactating woman or a woman who intends to become pregnant within 30 days following vaccination.

• Administration of immunoglobulins and/or any blood products within the 120 days preceding study entry or planned administration during the study period

• Administration of chronic (defined as more than 14 days) immunosuppressant's or other immune modifying drugs within 6 months of study entry

• Any other significant finding that in the opinion of the investigator would increase the risk of the individual having an adverse outcome from participating in this study

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Ebola Virus Disease
• Hemorrhagic Fever, Ebola
• Virus Diseases

Intervention

Biological:
• VSV-ZEBOV
VSV-ZEBOV

Locations

Country	Name	City	State
Kenya	KEMRI Wellcome Trust Research Programme	Kilifi	Coast

Sponsors (8)

Lead Sponsor	Collaborator
University of Oxford	Albert Schweitzer Hospital, Institute of Tropical Medicine, University of Tuebingen, Philipps University Marburg Medical Center, Universitätsklinikum Hamburg-Eppendorf, University Hospital, Geneva, Wellcome Trust, World Health Organization

Country where clinical trial is conducted

Kenya, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The nature, frequency, and severity of adverse events (AEs) and/or serious adverse events (SAEs) with causal link to the study intervention	To evaluate the safety and tolerability of two different doses of VSV?G-ZEBOV vaccine	Days 0-30	Yes
Secondary	Incidence and severity of local and systemic reactogenicity signs and symptoms		Day 0-28	Yes
Secondary	Incidence of unsolicited adverse events (AEs)		Days 0-28	Yes
Secondary	Incidence of serious adverse events (SAEs)		Days 0-365	Yes
Secondary	Distribution of values of safety laboratory measures at baseline and at follow-up visits post-vaccination	The distribution of values of safety laboratory measures will include the assessment of complete blood count (with differential white cell count), creatinine and alanine transaminase levels at baseline and day 7 and 30 following vaccine administration.	Day 0-30	Yes
Secondary	Persistence of titres of ZEBOV-specific IgG antibodies		0-180 days	No
Secondary	Detection, magnitude and duration of VSV-ZEBOV viraemia and shedding	The detection and concentration (copies/ml) of rVSV (viral shedding) will determined in blood, urine, or saliva samples to evaluate VSV vaccine viraemia following vaccine administration. The duration will be determined by the last timepoint with detectable viraemia.This is a composite measure.	Day 1, 3 and 7	Yes
Secondary	Titres of neutralising ZEBOV-specific IgG antibodies		Days 7, 30, 60, 90, 180 and 365	No
Secondary	Pattern of ZEBOV specific T cell responses		Days 7, 30, 90, 180 and 365	No
Secondary	Titers of ZEBOV-specific IgG antibodies	Important for dose selection	Days 0-28	No